News
SNDX ▼ -17.6% - Syndax Pharmaceuticals, Inc.
SNDX ▼ -17.6% - Syndax Pharmaceuticals, Inc.
$SNDX - Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
12-OCT-2026 04:01 PM ET
Share this post
More filings for $SNDX
SNDX - Syndax Pharmaceuticals, Inc. - SEC Filing Update (10-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 10, 2026SNDX ▲ +1.4% - Syndax Pharmaceuticals, Inc.Nov 4, 2026SNDX ▲ +1.4% - Syndax Pharmaceuticals, Inc.Nov 4, 2026SNDX ▼ -6.1% - Syndax Pharmaceuticals, Inc.Nov 2, 2026SNDX ▼ -6.1% - Syndax Pharmaceuticals, Inc.Nov 2, 2026SNDX ▼ -0.7% - Syndax Pharmaceuticals, Inc.Oct 30, 2026
View full $SNDX filing history →💬 Comments
Loading comments…
Leave a comment
